SPY
777.63
+0.48%
QQQ
750.75
+0.42%
BTC/USD
82,751.43
+1.30%
DIA
514.80
+0.62%
GLD
384.41
+1.53%
TLT
77.77
−0.13%
US
Sign in
Register
My Account
Benzinga
Markets & News
Markets
Stocks & Sectors
Stocks
Ratings & Research
Ratings
Trading
Trading
Screeners & Lists
Screeners
Learn
Learn
Premium
Premium Services
Markets & News
Breaking headlines, the trading day, and the calendars that move it.
Stocks & Sectors
Research any ticker, then drill into sectors, ratings, and options.
Ratings & Research
Wall Street calls, insider moves, and Benzinga's own stock rankings.
Trading
Options flow, trade calculators, and ideas for active traders.
Screeners & Lists
Filter the market your way, or start from a curated list.
Learn
Pick a broker, grow your savings, and protect what you've built.
Premium Services
Edge
Ratings, signals & screens
Pro
Real-time news & data terminal
Research
Trade alerts & newsletters
APIs
Market data licensing
All sections
Vir Biotechnology Inc
VIR
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$11.70
0.58
5.22%
Last update: Oct 9, 12:07 PM
$11.15
0.03
0.27%
Get Report
Overview
News
Earnings Forecast
Financials
Sentiment
Ownership
Compare
Options
Stock Report
Privacy Manager
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga
Edge
Benzinga
Research
Benzinga
Pro
Logout
Vir Biotechnology Analyst Price Targets
Wall Street analyst price targets and consensus rating for Vir Biotechnology (VIR).
Analyst Ratings News
PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $22
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $20 to $22.
Benzinga Newsdesk
PRO
Morgan Stanley Maintains Overweight on Vir Biotechnology, Raises Price Target to $27
Morgan Stanley analyst Michelle Gilson maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $23 to $27.
Benzinga Newsdesk
PRO
Leerink Partners Maintains Outperform on Vir Biotechnology, Raises Price Target to $21
Leerink Partners analyst Roanna Ruiz maintains Vir Biotechnology (NASDAQ:VIR) with a Outperform and raises the price target from $20 to $21.
Benzinga Newsdesk
Semtech To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
Wall Street analysts changed outlook on top names. For full view of changes, including upgrades/downgrades, see analyst ratings page.
Avi Kapoor
PRO
HC Wainwright & Co. Maintains Buy on Vir Biotechnology, Raises Price Target to $20
HC Wainwright & Co. analyst Patrick R. Trucchio maintains Vir Biotechnology (NASDAQ:VIR) with a Buy and raises the price target from $15 to $20.
Benzinga Newsdesk
PRO
Barclays Maintains Overweight on Vir Biotechnology, Raises Price Target to $30
Barclays analyst Etzer Darout maintains Vir Biotechnology (NASDAQ:VIR) with a Overweight and raises the price target from $26 to $30.
Benzinga Newsdesk
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch
AbbVie Inc
NYSE:ABBV
$275.14
1%
Amgen Inc
NASDAQ:AMGN
$411.13
0.91%
Gilead Sciences Inc
NASDAQ:GILD
$149.6
1.7%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
$508.85
1.11%
Moderna Inc
NASDAQ:MRNA
$209.09
6.14%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
$746.28
0.91%
Natera Inc
NASDAQ:NTRA
$392.9
2.13%
argenx SE
NASDAQ:ARGX
$818.02
-0.07%
Revolution Medicines Inc
NASDAQ:RVMD
$190.46
1.24%
BeOne Medicines Ltd
NASDAQ:ONC
$344.72
1.45%
Show all 10 related companies
